We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray Wins 7 TomoTherapy Orders from NHS, Stock Up
Read MoreHide Full Article
Shares of Accuray Inc. (ARAY - Free Report) increased almost 4% to close at $5.12 on Jun 16, following the news that the company has won seven TomoTherapy System orders from NHS Supply Chain in the U.K. This is the largest order from a single customer in the company’s history.
The order win suggests growing usefulness of the TomoTherapy system in providing radiation therapy and radiosurgery treatments. The NHS Supply Chain order also demonstrates continuing strong demand for the TomoTherapy system.
We note that NHS is a bigger organization as compared to the community or regional hospitals that have became the primary customer base for the system in recent times. The win will help Accuray solidify its international footprint over the long haul.
Since the deal has already been recorded as backlog, volumes will increase significantly, which will boost gross orders in the fourth quarter of fiscal 2016. Notably, gross orders increased 9% year over year (18% at constant currency) to $64.9 million in third-quarter 2016.
Accuray is now expected to beat its full-year 2016 gross order target of $280 million and $290 million, which was slashed from $295 million at the end of the third quarter. Meanwhile, revenues are forecasted in the range of $395–$405 million.
We believe that continued penetration and market share gains by the TomoTherapy system in single and dual vault accounts will drive gross order growth in fiscal 2017. Additionally, continued momentum in replacement sales and improvement in CyberKnife system sales are expected to drive growth.
Moreover, anticipated 510(k) approval with the FDA for Radixact treatment delivery system (next-generstion TomoTherapy platform), Precision Treatment Planning System and iDMS Data Management System are key catalysts for the long term.
Zacks Rank & Key Picks
Accuray carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are CryoLife , IRadimed (IRMD - Free Report) and Masimo Corp (MASI - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Accuray Wins 7 TomoTherapy Orders from NHS, Stock Up
Shares of Accuray Inc. (ARAY - Free Report) increased almost 4% to close at $5.12 on Jun 16, following the news that the company has won seven TomoTherapy System orders from NHS Supply Chain in the U.K. This is the largest order from a single customer in the company’s history.
The order win suggests growing usefulness of the TomoTherapy system in providing radiation therapy and radiosurgery treatments. The NHS Supply Chain order also demonstrates continuing strong demand for the TomoTherapy system.
We note that NHS is a bigger organization as compared to the community or regional hospitals that have became the primary customer base for the system in recent times. The win will help Accuray solidify its international footprint over the long haul.
Since the deal has already been recorded as backlog, volumes will increase significantly, which will boost gross orders in the fourth quarter of fiscal 2016. Notably, gross orders increased 9% year over year (18% at constant currency) to $64.9 million in third-quarter 2016.
ACCURAY INC Price and Consensus
ACCURAY INC Price and Consensus | ACCURAY INC Quote
Accuray is now expected to beat its full-year 2016 gross order target of $280 million and $290 million, which was slashed from $295 million at the end of the third quarter. Meanwhile, revenues are forecasted in the range of $395–$405 million.
We believe that continued penetration and market share gains by the TomoTherapy system in single and dual vault accounts will drive gross order growth in fiscal 2017. Additionally, continued momentum in replacement sales and improvement in CyberKnife system sales are expected to drive growth.
Moreover, anticipated 510(k) approval with the FDA for Radixact treatment delivery system (next-generstion TomoTherapy platform), Precision Treatment Planning System and iDMS Data Management System are key catalysts for the long term.
Zacks Rank & Key Picks
Accuray carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical space are CryoLife , IRadimed (IRMD - Free Report) and Masimo Corp (MASI - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>